Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 392-393

  Tay, Kok Hoon ^a   Lip, Gregory Y H ^a   Lane, Deirdre A ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY EMBOLISM; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LETTER; LUNG EMBOLISM; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FRAIL ELDERLY; HEMORRHAGE; HUMANS; MALE; RISK; THROMBOPHILIA; VITAMIN K; WARFARIN;

EID: 68149091948     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832aec47     Document Type: Letter

References (9)

1. Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100:16-17.
2. Mant JW. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost 2008; 100:14-15.
3. Tincani E, Baldini P, Crowther MA, Zanasi A, Ferrari P, Cenci AM, Rioli G. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis 2009; 20:47-51.
4. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in out-patients treated with warfarin. Am J Med 1998; 105:91-99.
5. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E, BAFTA investigators; Midland Research Practices Network (MidRec). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA); a randomised controlled trial. Lancet 2007; 370:493-503.
6. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390-1396.
7. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting haemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-319.
8. 2 score. Thromb Res2007; 121:347-352.
9. van Walraven C, Jennings A, Oake N, Fergusson D, Forster A.Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest 2006; 129:1155-1166.